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INTRODUCTION
Anti-Mullerian hormone (AMH) and inhibin B are mem-
bers of the transforming growth factor βsuperfamily and
both are expressed by the granulosa cells. Circulating levels
of AMH and inhibin B are correlated with primordial folli-
cle recruitment, suggesting that they may be potential clini-
cal markers for ovarian reserve. Numerous studies have report-
ed that basal serum levels of AMH (1-5) or inhibin B (5-7)
are good predictor of ovarian response in patients undergo-
ing ovarian hyperstimulation and in vitro fertilization (IVF).
Several reports also indicate that basal serum levels of AMH
is a more discriminatory marker of ovarian response than basal
follicle stimulating hormone (FSH), inhibin B, or estradiol
(8-10). 
However, there were few reports addressing the clinical
significance of AMH and/or inhibin B levels measured at
late follicular phase during ovarian hyperstimulation. 
Serum and follicular AMH levels at the time of oocyte
retrieval are positively correlated with the number of mature
follicles and oocytes retrieved (11). A recent report indicat-
ed that serum AMH values at the time of human chorionic
gonadotropin (hCG) administration are also correlated sig-
nificantly with the number of mature follicles, number of
oocytes retrieved and serum estradiol levels (12). Moreover,
AMH levels are correlated significantly with a greater num-
ber of 6-cell embryos and better embryo morphology score. 
Serum inhibin B levels at ovulation triggering day and
the levels in follicular fluids at the time of oocyte retrieval
are strongly correlated with the number of oocytes retrieved
(13). Serum (14) and follicular fluid (15) levels of inhibin B
at ovum pick up are also correlated positively with the num-
ber of oocytes collected and were predictive of clinical preg-
nancy. Serum inhibin B levels measured around late follicu-
lar phase during ovarian hyperstimulation could predict the
number of oocytes retrieved both in normal and poor respon-
der (16). 
Since AMH is secreted mainly in preantral and early small
antral follicle (17, 18), the circulating AMH level decreases
through maturing follicle in normal menstrual cycle, and
657
Byung Chul Jee*, Seung Yup Ku
� , 
Chang Suk Suh*
,� , Ki Chul Kim
� ,
Won Don Lee
�, Seok Hyun Kim
� , 
and On behalf of the Seoul National 
University College of Medicine Assisted
Reproductive Technology (SMART) Study
Group 
Department of Obstetrics and Gynecology*, Seoul
National University, Bundang Hospital, Seongnam;
Department of Obstetrics and Gynecology
� , Seoul
National University, College of Medicine, Seoul; 
Hamchoon Women’s Clinics
� , Seoul; Maria Infertility
Clinics
�, Seoul, Korea
Address for correspondence
Seok Hyun Kim, M.D.
Department of Obstetrics and Gynecology, Seoul
National University, College of Medicine, 28 Yeongeon-
dong, Jongno-gu, Seoul 110-744, Korea 
Tel : +82.2-2702-3773, Fax : +82.2-762-3599
E-mail : seokhyun@snu.ac.kr
J Korean Med Sci 2008; 23: 657-61
ISSN 1011-8934
DOI: 10.3346/jkms.2008.23.4.657
Copyright � The Korean Academy
of Medical Sciences
Serum Anti-Mullerian Hormone and Inhibin B Levels at Ovulation 
Triggering Day Can Predict the Number of Immature Oocytes
Retrieved in In Vitro Fertilization Cycles
The aim of this study was to investigate whether serum levels of anti-Mullerian hor-
mone (AMH) and inhibin B at ovulation triggering day correlate with the number of
immature oocytes obtained from stimulated in vitro fertilization (IVF) cycles. Fifty-
nine consecutive cycles of ovarian hyperstimulation and IVF were selected from
45 women who had tubal (n=18) or unexplained infertility (n=27) and obtained at
least one oocyte. Serum levels of AMH and inhibin B at ovulation triggering day
were measured by enzyme-linked immunosorbent assay (ELISA). Univariate anal-
ysis and multiple regressions revealed that serum AMH or inhibin B levels were
significantly correlated with immature oocyte count and the correlation coefficients
were higher compared to the mature oocyte count. Serum AMH and inhibin B lev-
els on triggering day seems to be more closely related with the immature oocyte
count and thus could be good predictors to determine the immature oocyte count
in IVF cycle.
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further decreases in FSH-treated cycles (19-21). In ovarian
hyperstimulation and IVF cycles, however, continued recruit-
ment of additional antral follicles during the stimulatory
phase results in higher AMH levels, thus it may be related
with the number of mature follicles and number of oocytes
retrieved. 
In contrast to AMH, inhibin B rises from early follicular
phase to reach a peak during mid-follicular phase (22) but
continues to increase during ovarian hyperstimulation (16).
This suggests that inhibin B is secreted by the developing
cohort of antral follicles (23).
Follicular pool at late follicular phase encompasses various
stages of follicular development during ovarian hyperstimu-
lation. Therefore, AMH and inhibin B levels at late follicu-
lar phase could reflect overall ovarian pool, including small
and large antral and mature follicles. However, follicular
AMH levels were reported to be three times higher in small
follicles (<12 mm) than large follicles (>16 mm) and serum
AMH levels were tightly correlated with the follicular lev-
els (11). These findings suggest that serum AMH levels more
reflect small antral follicular pool, thus we postulated serum
AMH levels at ovulation triggering day could be related with
the number of immature oocytes obtained. Although previ-
ous studies by other researchers demonstrated that serum
AMH (12) or inhibin B (13, 16) values at the time of hCG
administration correlated significantly with the number of
oocytes retrieved, they described only the number of total or
mature oocytes. The aim of this study was to investigate
whether serum levels of AMH and/or inhibin B at ovula-
tion triggering day correlate with the number of immature
oocytes obtained from stimulated IVF cycles.
MATERIALS AND METHODS
Fifty-nine IVF cycles from 45 infertile couples were recruit-
ed in which at least one oocyte was obtained between May
2005 and November 2006. The characteristics of the study
subjects were presented in Table 1. Only women with tubal
(n=18) or unexplained infertility (n=27) were included.
Ovulatory factor such as polycystic ovary syndrome (PCOS)
was entirely excluded since women with PCOS may have
unusually higher serum AMH levels during ovarian hyper-
stimulation (21). Patients with present or past history of
ovarian endometriomas were also excluded. We obtained an
approval from Institutional Review Board of Seoul National
University Bundang Hospital for the measurement of AMH
and inhibin B from patients’ frozen sera.  
Ovarian hyperstimulation was performed using recombi-
nant FSH (rFSH, Gonal-F
�, Serono, Geneva, Switzerland)
(31 cycles) or combination of rFSH with urinary hMG (Me-
nogon
�, Ferring, Malmo, Sweden in 11 cycles, and Perg-
onal
�, Serono in 15 cycles). Urinary hMG only were used in
two cycles. The pituitary was suppressed only by GnRH
antagonist. When mature leading follicle reached 14 mm
in diameter, GnRH antagonist (Cetrotide
�, Serono) 0.25 mg/
d was started until HCG administration. When mature lead-
ing follicle(s) reached 19 mm in diameter, recombinant hCG
(Ovidrel
�, Serono) 0.25 mg was given for final ovulation trig-
gering and then oocytes were retrieved 35-36 hr later. During
the study period, almost all follicles over 10 mm in diameter
were aspirated strictly. 
In conventional IVF cycles (n=25), the maturity of oocytes
was initially assessed by their morphological criteria in ref-
erence of cumulus cells. When immature oocytes were sus-
pected, they were treated with phosphated buffered saline
(PBS) solution including 0.1% hyaluronidase (Cook, Bris-
bane, Australia), and then, the cumulus cells were removed
mechanically by pipetting. In intracytoplasmic sperm injec-
tion (ICSI) cycles (n=34), cumulus-enclosed oocytes were
treated with 0.1% hyaluronidase, and the cumulus cells were
removed mechanically by pipetting. Finally, immature oocytes
were defined by the absence of the first polar body, and then
classified as germinal vesicle (GV) or metaphase I stage depend-
Mean SD Median Range
Female age (yr) 33.4 3.9 33.0 28-43
Duration of infertility (yr) 4.5 2.6 4.0 1-14
Basal FSH of female (mIU/mL) 5.9 4.3 4.9 1.5-18.9
Number of IVF cycle 1.9 1.9 1.0 1-13
Dose of gonadotropins (ampoules) 23.4 4.9 21.0 14-40
Estradiol concentration at ovulation triggering (pg/mL) 1017.2 640.4 947.0 177-2662
Number of total oocytes 7.2 4.0 7.0 1-21
Number of mature oocytes 4.8 2.8 4.0 1-11
Number of immature oocytes 2.4 2.4 2.0 0-10
Number of embryos transferred 2.6 0.8 3.0 1-5
AMH concentration at ovulation triggering (ng/mL) 0.90 0.83 0.67 0.05-2.99
Inhibin B concentration at ovulation triggering (pg/mL) 1013.2 984.6 755.1 34.4-4477.5
Table 1. The clinical characteristics of 59 IVF cycles from 45 infertile women including serum levels of anti-Mullerian hormone (AMH)
and inhibin B
All numerical variables showed a normal distribution.
IVF, in vitro fertilization; FSH, follicle-stimulating hormone.
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ing on visible GV. The mature oocyte was determined as a
presence of the first polar body under the stereomicroscope. 
Mature oocytes were inseminated by conventional method
or ICSI. Immature oocytes were cultured (MI oocytes for 4
hr and GV up to 44 hr) in organ culture dish containing 1
mL of each G2 medium (Vitrolife, Kungsbacka, Sweden) at
37℃, 5% CO2 with high humidity. If matured, they were
fertilized by ICSI. Normal fertilization was confirmed when
two distinct pronuclei were present 16-18 hr later. The
cleaved embryos with good quality, either from in vivo or in
vitro matured oocytes, were transferred transcervically 3 days
after insemination. Pregnancies were followed by serial serum
β -hCG and ultrasonogram (USG).
Blood samples were collected on the day of hCG adminis-
tration, and serum aliquots were immediately separated, then
frozen at -80℃ till assay. The concentrations of serum estra-
diol were measured using a radioimmunoassay kit (TKE21,
Diagnostic Products Corporation, U.S.A.). AMH and inhib-
in B concentrations were measured by sensitive enzyme-link-
ed immunosorbent assay (ELISA) (MIS/AMH; DSL-10-14400,
Inhibin B; DSL-10-84100i, Diagnostic Systems Laborato-
ries, Webster, Texas, U.S.A.). The sensitivity of AMH was
<0.017 ng/mL and the intra-assay coefficient of variation
(CV) was 4.6% at 0.144 ng/mL. The sensitivity of inhibin
B was <7 pg/mL and the intra-assay CV was 5.6% at 472
pg/mL.
Statistical analysis was performed using MedCalc (ver.
4.15, MedCalc Software, Mariakerke, Belgium). A p value
<0.05 was considered statistically significant. 
RESULTS
Approximately one third of the retrieved oocytes were
immature oocyte in our series (33.7%, 144/427). The over-
all maturation and fertilization rate for immature oocyte was
56.9% (82/144) and 61.0% (50/82), respectively. Embryo
transfer was possible in all study subjects except one cycle.
Up to five embryos were transferred and the resultant preg-
nancy rate was 25.9% per transfer (15/58). Between pregnant
and non-pregnant cycles, there were no differences in oocytes
number and serum levels of AMH, inhibin B or estradiol.
Univariate analysis revealed that the number of immature
as well as mature oocytes was positively correlated with serum
AMH, inhibin B and estradiol levels, respectively (Table 2).
In serum AMH and inhibin B, the correlation coefficients
for immature oocyte were slightly higher than those for mature
oocyte. AMH levels had a strong positive correlation with
inhibin B. Either AMH or inhibin B levels were correlated
positively with estradiol levels. There was no relation between
mature and immature oocyte count.
Since serum levels of AMH, inhibin B and estradiol may
reflect overall oocyte pool including mature (MO) and imma-
ture oocytes (IM), we tested multiple regressions and the
following equations were generated. 
AMH (ng/mL)=0.1312+0.0874 [MO]+0.1417 [IM] (r=
0.5424, p=0.008)
Inhibin B (pg/mL)=-188.7851+130.5844 [MO]+235.8635
[IM] (r=0.7318, p=0.022)
Estradiol (pg/mL)=234.1401+118.9406 [MO]+87.0733
[IM] (r=0.6593, p=0.014)
Multiple regressions showed that numbers of mature and
immature oocytes were still independently correlated with
three markers. Multiple regressions also indicated that all of
three markers could reflect the combined pool of mature and
immature oocytes with a statistical significance. These equa-
tions also indicate serum AMH and inhibin B levels measured
on triggering day were more closely related with the imma-
ture oocyte count than mature oocyte count in IVF cycle.
DISCUSSION
Our results clearly demonstrated that the number of imma-
ture as well as mature oocytes is independently correlated
with serum AMH and inhibin B levels measured on ovula-
tion triggering day. Very interestingly, the correlation coef-
ficients from univariate analysis were higher in the number
of immature oocytes than number of mature oocytes. This
means that the number of immature oocytes have a better
correlation with serum AMH and inhibin B levels. We could
generate multiple regression equations in the hypothesis that
number of retrieved oocytes represents follicular pool at the
IVF, in vitro fertilization; R, Pearson’s correlation coefficient; NS, not sig-
nificant.
Proportions of mature or immature oocytes indicate the proportion of
mature or immature oocytes per total number of oocytes per cycle.
AMH (ng/mL) Inhibin B 
(pg/mL)
Estradiol 
(pg/mL)
Number of total  R=0.5309 R=0.7090 R=0.6538
oocytes p=0.0000 p=0.0000 p=0.0000
Number of mature  R=0.3591 R=0.4599 R=0.5747
oocytes p=0.0052 p=0.0002 p=0.0000
Proportion of mature  R=-0.2231 R=-0.2075 R=-0.0901
oocytes p=0.0894 p=0.1147 p=0.4976
Number of immature  R=0.4542 R=0.6299 R=0.4029
oocytes p=0.0003 p=0.0000 p=0.0016
Proportion of immature  R=0.2231 R=0.2075 R=0.0901
oocytes p=0.0894 p=0.1147 p=0.4976
Inhibin B (pg/mL) R=0.7678 --
p=0.0000
Estradiol (pg/mL) R=0.4046 R=0.5168 -
p=0.0015 p=0.0000
Table 2. Correlation analysis of serum anti-Mullerian hormone
(AMH), inhibin B and estradiol at the time of ovulation triggering
day relevant to number of oocytes retrieved in 59 IVF cycles
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time of oocyte retrieval. From the equations, we found again
that number of immature oocytes could be a better contrib-
utor to determine serum levels of AMH and inhibin B. 
Although previous studies by other researchers demon-
strated that serum values of AMH (12) or inhibin B (13, 16)
at the time of ovulation triggering correlate significantly with
the number of oocytes retrieved, they did not describe the
number of immature oocytes separately. Our findings are in
agreement with those of the previous studies in that serum
AMH or inhibin B at ovulation triggering day have a signif-
icant positive correlation with the number of total or mature
oocytes collected. Moreover, we found for the first time that
serum levels of AMH and inhibin B could be good predictors
to determine the number of immature oocytes retrieved in
IVF cycles.
At the time of ovulation triggering, follicular pool with
various sizes exists within ovary. During ovarian stimulation,
the oocyte population at the time of hCG may be heteroge-
neous and this leads to retrieval of oocytes at different stages
of maturation. Immature oocytes at the time of oocyte retrieval
may be originated from small antral follicles or from large
preovulatory follicles unresponsive to hCG. In one study,
61.8% of immature oocytes are obtained from small antral
follicles (7-12 mm) and the remaining from larger follicles
(>12 mm) (24). 
In IVF cycles, 10-15% of oocytes are generally obtained
as immature form. Although they represent a compromised
group with low developmental competence, those are valu-
able source for surplus oocytes if they can be matured in vitro.
The clinical use of oocytes matured in vitro for IVF is more
important especially in poor responders; thereby the needs
for development of in vitro maturation are increasing (25).
In the present study, 33.7% of oocytes were retrieved as imma-
ture form. This higher rate might be principally attributed
to our strict policy to puncture all follicles over 10 mm in
diameter during the period of study. The selection of those
who were used GnRH antagonist could be another factor. A
slightly higher immaturity was reported in GnRH antago-
nist cycles compared to GnRH agonist cycles (24).
We also found a strong positive correlation between serum
concentrations of AMH and inhibin B at ovulation trigger-
ing day. Serum estradiol levels also correlated positively with
either serum AMH or inhibin B levels. These strong corre-
lations indicate that growing follicular pool produces AMH,
inhibin B as well as estradiol into the circulation, and thus
suggest that serum AMH and inhibin B give no additive
information over conventional measurement of serum estra-
diol levels. Serum AMH and inhibin B may be valuable in
that these protein markers represent preferentially imma-
ture oocyte count, as shown by our study.
In the present study, the mean serum level of AMH at
ovulation triggering day was 0.90 ng/mL (range: 0.05-2.99
ng/mL) and this was quite lower than 2.7 ng/mL (range: 0-
28.5 ng/mL) reported by Silberstein et al. (12) However, it
cannot be directly compared since the method of measure-
ment was different. We used ELISA kits purchased from
Diagnostic Systems Laboratories (DSL), and it was reported
that AMH levels are almost 4.6-fold lower with the DSL kit
compared to the Beckman Coulter kit (26). One study using
the Beckman Coulter kit reported the median serum level of
AMH was 1.44 ng/mL on the day of oocyte retrieval (range:
0.38-4.96 ng/mL) (11). Serum AMH levels on the day of
oocyte retrieval may be lower than those in ovulation trig-
gering day because hCG-induced luteinization curtails fol-
licular AMH production (27). Therefore, serum AMH val-
ues may be different according to the time of measurement
and the ELISA kits used. 
In conclusion, our study demonstrated that the number
of immature as well as mature oocytes retrieved in stimulat-
ed IVF cycles is independently correlated with serum AMH
and inhibin B levels measured on ovulation triggering day.
Our results also indicate that serum AMH and inhibin B
levels on triggering day are more closely related with imma-
ture oocyte count, thus serum levels of AMH and inhibin B
seem to be good predictors to determine the immature oocyte
count in IVF cycle.
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